Retrophin, Inc. (NASDAQ: RTRX) today announced the presentation of new data from physician-initiated treatment with fosmetpantotenate (RE-024), the Company's novel ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE